# Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

> **NCT04179175** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 703 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** secukinumab
- **DRUG:** secukinumab

## Key facts

- **NCT ID:** NCT04179175
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-18
- **Primary completion:** 2023-05-26
- **Final completion:** 2026-07-15
- **Target enrollment:** 703 (ACTUAL)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04179175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04179175, "Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04179175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*